CSL Grants

Programs that address identified knowledge gaps in ANCA vasculitis (AAV) and IgA nephropathy (IgAN) to increase understanding of disease burden including epidemiology.

Programs that enhance awareness of appropriate diagnostic assessment criteria including biomarkers to improve timely diagnostic accuracy in ANCA magnifiers and IgA nephrologist.

Programs that discuss efficacy and safety of AAV or IgAN disease specific therapies.

Programs that foster knowledge of appropriate management and assessment of patient outcomes including health care usage utilization.

Programs that support education, data dissemination and recommendation of clinical data to improve patient outcomes in AAV, IgAN and iron deficiency.

Programs that provide education on the use of 4F-PCC and/or fibrinogen concentrate in emergent bleeding and acute hemorrhage scenarios and health economic aspects of blood management and concentrate administration.

Programs that advance principles of Patient Blood Management (PBM).

Programs that educate on importance of FIX activity levels and their correlation with clinical, quality of life, and socioeconomic outcomes in hemophilia B.

Programs designed to educate on provider and patient real-world experience with hemophilia B gene therapy.

Programs that enhance clinician’s knowledge of hereditary angioedema types 1, 2 and HAE with normal C1 inhibitor including but not limited to: epidemiology, clinical signs and symptoms, pathophysiology (e.g. role of factor XIIa and C1 inhibitor in angioedema), guideline driven management and current/novel treatments.

Role of shared decision making between HCP and patient in determining their appropriate HAE management plan.

Programs that raise awareness around the HAE patient and caregiver journey/experience, real-world evidence, and quality of life aspects of their disease.

Programs pertaining to identification of unmet needs and burden of HAE, including its psychosocial impact for patients and caregivers.

Programs pertaining to improvements in diagnosis of HAE.

Programs that enhance awareness of appropriate CIDP diagnostic assessment criteria, improve timely diagnostic accuracy, or braise clinical practice gaps in neuromuscular disease management.

Programs that foster knowledge of appropriate management and assessment of patient outcomes in CIDP including patient preferences for treatments.

Programs that expand the knowledge of CIDP disease management using intravenous and subcutaneous immunoglobulin therapy through education on the clinical data, including infusion training of healthcare professionals.

Programs that raise awareness of PID disease burden and improve accurate diagnosis, particularly in adult populations with a history of noninfectious complications (e.g., chronic lung disease, autoimmune diseases).

Programs that expand the knowledge of therapeutic strategies for management of antibody deficiencies.

Programs that enhance awareness of appropriate diagnostic assessment criteria and improve timely diagnostic accuracy in PID.

Programs that foster knowledge and improve quality and delivery of care, utilization of appropriate therapy, lead to the creation of guidelines and assessment of PID patient outcomes.

Programs that expand the knowledge of therapeutic strategies for management of antibody deficiencies.

Programs that enhance awareness of appropriate diagnostic assessment criteria and improve timely diagnostic accuracy.

Programs that foster knowledge and improve quality and delivery of care, utilization of appropriate therapy, lead to the creation of guidelines and assessment of patient outcomes.

Programs that discuss innovations in the delivery of immunoglobulins.

A: You will receive a Grant submission confirmation via email which will include your Request ID. Please keep this for your records. This email will also provide a link to the Grant application to continue to follow up on the request.

A: You will receive an email notification of the status of the Grant after the Committee completes the review.